CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drug
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drug" is generating significant coverage in the Business category, with 6 articles from 6 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Pharmaceutical Executive, Reuters, Seeking Alpha and Bloomberg.com. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 39d ago.
Quick answers
Why is "CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drug" trending?
Because 6 independent news sources published 6 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (6)
- CSL & Alentis Enter $1.6 Billion Global Partnership Pharmaceutical Executive · 42d ago
- CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis Reuters · 42d ago
- CSL strikes $1.6B deal with Alentis for experimental kidney, liver drug (CSLLY:OTCMKTS) Seeking Alpha · 42d ago
- CSL Agrees to Pay Up to $1.6 Billion in Rare Disease Drug Deal Bloomberg.com · 42d ago
- CSL to pay $355M upfront to co-develop Alentis’ kidney and liver drug Endpoints News · 42d ago
- CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drug fiercebiotech.com · 42d ago
Topics
Related trends
BMW M2 Gets A Dramatic 3.0 CSL Makeover
5 news sources are covering this Technology story right now — PULSE is tracking how fast it spreads.